The invention provides construction of a model of co-expression uptake of a carrier and a
drug-metabolizing
enzyme. The construction comprises the following steps: amplifying a human
gene OAT1cDNA used as a template to obtain a human OAT1
gene segment, connecting the obtained human OAT1
gene segment to a carrier pcDNA3.1(+) to obtain a
plasmid pcDNA3.1(+) / OAT1, transfecting MDCK (Madin Darby
Canine Kidney) cells, and screening to obtain MDCK-hOAT1 cells in which the OAT1 is highly expressed; connecting a human CYP1A2 gene segment to a carrier pcDNA3.1(+) / Hygro(+) to obtain a
plasmid pcDNA3.1 / Hygro(+) / CYP1A2, transfecting the MDCK-hOAT1 cells, screening by using a
hygromycin B to obtain cells of co-expression of OAT1 and CYP1A2, then carrying out mRNA
verification on the cells and also carrying out
functional verification by virtue of a classic substrate and an inhibitor. The
cell model can be applied to cellular-level screening based on the medical toxic effects of OAT1 and CYP1A2, and therefore, prediction of the synergistic effect of the two proteins in a
medicine disposition process is realized and a basis can be provided for clinical rational medications. The
cell model is rational in design and high in
repeatability.